Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for allegedly making false or misleading statements regarding its immuno-oncology treatments, leading to significant investor losses during the specified Class Period [1][2]. Group 1: Company Overview - Agenus Inc. is a biotechnology company focused on developing immuno-oncology treatments, specifically two main products: balstilimab and botensilimab (AGEN1181) [2]. - Balstilimab is an anti-PD-1 treatment that has completed a Phase 2 trial for second-line cervical cancer, while botensilimab is a CTLA-4 blocking antibody currently in Phase 2 trials for pancreatic cancer and melanoma [2]. Group 2: Allegations and Legal Action - The class action lawsuit claims that Agenus failed to disclose that the combination of botensilimab and balstilimab was less effective than represented and that the clinical results were overstated [2]. - On July 18, 2024, Agenus disclosed that the FDA advised against using the results of their immunotherapy combination for seeking Accelerated Approval, stating that the observed response rates might not lead to improved survival [3]. - Following this announcement, Agenus' stock price experienced a nearly 59% drop, indicating a significant impact on investor value [3].